FDA Approves Expanded Indication for Hyqvia to Treat Pediatric Primary Immunodeficiency
April 12th 2023During the 12-month trial period, Hyqvia was shown to be efficacious treating the occurrence of acute serious bacterial infections in children aged 2 through 16 years with primary immunodeficiency.
Read More
Real-World Efficacy, Safety of Tixagevimab/Cilgavimab in Patients With Cancer After EUA Revision
The role of monoclonal antibodies in minimizing COVID-19–related complications remains important to assess.
Read More